Execs On The Move: July 2023
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You may also be interested in...
The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.
The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.
The UK-based company is hoping to quickly take market share with its blood-based diagnostic that uses epigenetic data to assist cancer diagnosis.